Key result
Ventilatory support and optimal cardiac therapy stabilize LVEF over 3 years in late-stage DMD.
Why the study?
The clinical outcome and sequential changes of cardiac function in late-stage Duchenne muscular dystrophy patients under ventilatory support and cardiac therapy were not well characterized.
Does adequate ventilatory support and optimal cardiac medication therapy stabilize cardiac function in patients with late-stage Duchenne muscular dystrophy?
Cohort (n=31)
No
Does adequate ventilatory support and optimal cardiac medication therapy stabilize cardiac function in patients with late-stage Duchenne muscular dystrophy?
p-value: p=0.320
In patients with late-stage Duchenne muscular dystrophy on ventilator support, cardiac function (LVEF) can remain stable into their mid-30s with optimal medical therapy.
Supports LVEF stability with ventilatory support in late DMD; hypothesis-generating and requires prospective confirmation before practice change.
OBJECTIVES: The purpose of this study was to investigate the clinical outcome as well as the sequential changes of cardiac function in late-stage Duchenne muscular dystrophy (DMD) patients by 2-dimensional echocardiography. METHODS: A total of 31 individuals (initial age: 21.6 ± 5.0 years, range: 15-35 years) with late-stage DMD (Swinyard-Deaver's stage 7 or 8) were enrolled. All of these patients had respiratory insufficiency and were on ventilator support. Sequential echocardiographic data were collected over at least 3 years. Repeated measures analysis of variance was used to compare changes in left ventricular ejection fraction (LVEF) over time. RESULTS: The sequential change in the mean LVEF showed no significant differences with initial, 1-, 2-, and 3-year follow-up LVEFs which were 42.2, 42.9, 43.8 and 42.6%, respectively (p = 0.320). In terms of the clinical outcome, all but 1 patient survived during the follow-up period of 46.5 ± 9.1 months. CONCLUSIONS: The cardiac function in late-stage DMD patients showed a stabilization of LVEF on adequate ventilatory support and optimal cardiac medication therapy until their mid-30s. In addition, considering the favorable clinical outcome in our study, the process of cardiac involvement in late-stage DMD may demonstrate that in some patients it is nonprogressive.
No takes yet. Share an insight, caveat, or question.
Kwon et al. (2012) conducted a cohort in Late-stage Duchenne muscular dystrophy (DMD) (n=31). Management with ventilatory support and cardiac medication was evaluated on Changes in left ventricular ejection fraction (LVEF) over time (p=0.320). In patients with late-stage Duchenne muscular dystrophy on ventilatory support, mean LVEF remained stable over 3 years (from 42.2% to 42.6%, p=0.320), with 30 of 31 patients surviving.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: